Viewing data from:

MIBELAS 24 FE

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | A206287 | LUPIN INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Mibelas 24 Fe (2023)

Total Spending

$18K

Total Claims

219

Beneficiaries

Avg Cost/Unit

$1.41

Spending Trend

$75K(2019)→$78K(2020)→$4K(2021)→$18K(2023)

5yr CAGR:-16.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 26, 2016	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.02MG;1MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 24, 2016

No patent or exclusivity listings for this strength.